|
No records
|
|
495 |
Nadhif M.H., Assyarify H., Irsyad M., Pramesti A.R., Suhaeri M. |
57189057498;57220927630;57220935587;57222624921;56183087500; |
Recent advances in 3D printed wound dressings |
2021 |
AIP Conference Proceedings |
2344 |
|
020021 |
|
|
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103522380&doi=10.1063%2f5.0047183&partnerID=40&md5=494f3e384ff38d4974127c234d704499 |
Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Department of Medical Physics, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Unit of Education, Research, and Training, Universitas Indonesia Hospital, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia |
Nadhif, M.H., Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia, Department of Medical Physics, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Assyarify, H., Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Irsyad, M., Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Pramesti, A.R., Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Suhaeri, M., Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia, Unit of Education, Research, and Training, Universitas Indonesia Hospital, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia |
Chronic and acute wounds interfere with personal aesthetics and appearance. Regarding the problematics, researchers enhance the functionalities of wound dressings. One of the enhancement approaches is using 3D printing technology. The use of 3D printing has enabled many types of wound dressings, including biodegradable multi-material, cell-laden, and drug-eluting wound dressings. The use of 3D printing even allows for a wound dressing with a 3D construct, facilitating the wound dressing placement at the wound bed. Unfortunately, the 3D printed wound dressing technology has never been reviewed, to the extent of our knowledge. In this report, we aim to reflect on the recent advances in 3D printed wound dressings. Reports regarding the 3D printed wound dressing were collected from the Google Scholar database. The search was limited from 2015 to 2020 with a logic search: "3D printed"AND "wound dressing,"which words can be found in the entire article. Irrelevant reports were excluded manually, thereby resulting in the 24 selected articles. The selected articles were subsequently reviewed in terms of the materials-efficacy analysis and 3D printing mechanism. The extracted information from all articles concluded that alginate is the most used material for 3D printed wound dressing, while the most used 3D printing mechanism is the pneumatic FDM. In terms of efficacy, wound dressings presented an antimicrobial performance against Gram-positive and Gram-negative bacteria, as well as biocompatibility to epidermis and dermis cells. © 2021 Author(s). |
|
|
American Institute of Physics Inc. |
0094243X |
9780735440869 |
|
Conference Paper |
- |
177 |
20880 |
|
|
|
496 |
Utomo M.S., Asmaria T., Malau D.P., Triwardono J., Kartika I., Dilogo I.H., Rahyussalim A.J. |
56180933900;57212340647;57208306899;57214135764;57218158170;56161962800;55212166100; |
Design criteria for cementless total hip arthroplasty: A retrospective study from cadaver implantation |
2021 |
AIP Conference Proceedings |
2344 |
|
020019 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103521074&doi=10.1063%2f5.0047288&partnerID=40&md5=d88d2b334a37cee012b14dd1543e1689 |
Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Department of Orthopedics and Traumatology, RSUPN Cipto Mangunkusumo, Jl. Diponegoro No. 71, Salemba, Jakarta, 10430, Indonesia |
Utomo, M.S., Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Asmaria, T., Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Malau, D.P., Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Triwardono, J., Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Kartika, I., Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Dilogo, I.H., Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia, Department of Orthopedics and Traumatology, RSUPN Cipto Mangunkusumo, Jl. Diponegoro No. 71, Salemba, Jakarta, 10430, Indonesia; Rahyussalim, A.J., Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia, Department of Orthopedics and Traumatology, RSUPN Cipto Mangunkusumo, Jl. Diponegoro No. 71, Salemba, Jakarta, 10430, Indonesia |
Total hip arthroplasty (THA) is the most frequent arthroplasty procedure performed worldwide including in Indonesia. To support Indonesian government initiative to establish a generic domestic THA implant, Research Center for Metallurgy and Materials - Indonesian Institute of Sciences in cooperation with Universitas Indonesia has designed and realized set of cementless titanium-based THA implant. Here we reported the result of first cadaver implantation for cementless titanium-based THA implant in Indonesia. There are three sets of cementless titanium-based THA implants implanted into the left leg of three cadavers. Implantation was performed simultaneously by three groups of orthopedic surgeons. There are three major aspects as evaluation from the cadaver implantation: design, material, and instrumentation. The current cementless titanium-based THA implant was designed based on the same template, material specification, process, and implanted using standard commercial instrumentation. As further directives, it is required to develop the cementless titanium-based THA implants with various shape and sizing in regard of Indonesia domestic requirement, appropriate coating for cementless implantation, refined material properties to facilitate the fabrication process, and customized instrumentation as a whole set of development within the development of the cementless titanium-based THA implant. © 2021 Author(s). |
|
|
American Institute of Physics Inc. |
0094243X |
9780735440869 |
|
Conference Paper |
- |
177 |
20880 |
|
|
|
497 |
Utomo M.S., Nadhif M.H., Bayani G.F.E., Whulanza Y. |
56180933900;57189057498;57222627409;36807053500; |
A low cost, off-the-shelf bioreactor as enabling technology for physiological modeling |
2021 |
AIP Conference Proceedings |
2344 |
|
050017 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103516555&doi=10.1063%2f5.0047233&partnerID=40&md5=321c75b01f581669d0c6f955fe9b2966 |
Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Department of Medical Physics, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Department of Physiology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Department of Mechanical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 16424, Indonesia; Research Center for Biomedical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 16424, Indonesia |
Utomo, M.S., Research Center for Metallurgy and Materials, Indonesian Institute of Sciences, PUSPIPTEK Area, 470 South Tangerang, Banten, 15314, Indonesia; Nadhif, M.H., Department of Medical Physics, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia, Medical Technology Cluster, Indonesia Medical Education and Research Institute (IMERI), Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Bayani, G.F.E., Department of Physiology, Faculty of Medicine, Universitas Indonesia, Jl. Salemba Raya No. 6, DKI Jakarta, 10430, Indonesia; Whulanza, Y., Department of Mechanical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 16424, Indonesia, Research Center for Biomedical Engineering, Faculty of Engineering, Universitas Indonesia, Kampus UI Depok, West Java, 16424, Indonesia |
Nowadays, tissue engineering has become a primary option for clinical treatment involving tissue damage or organ failure. One important enabling technological aspect for tissue engineering to produce successful outcomes is bioreactor where cells could be grown under certain conditions mimicking real physiological conditions and be prepared for in vivo integration before implantation to the patients. Physical stimulation by mechanical and electrical means could improve the development of engineered tissue to mimic the actual tissue. Mechanical stimulation could improve cellular function by improving the integrity and organization of the engineered tissue while electrical stimulation can improve the conductivity and contractility of tissue construction. The electric field would stimulate cellular calcium activity which could stimulate cell integration and gap junction formation. Thus, it is necessary to develop a bioreactor that is capable to provide a well-controlled environment and proper combination of mechanical and electrical stimulation to optimize the process of tissue engineering. Here we build a bioreactor that is capable to stimulate the engineered tissue mechanically and electrically to improve the tissue's contractile performance and functional maturity through an isovolumic contraction. The mechanical stimulation is generated by harmonic inflation and deflation of a balloon while the electrical stimulation is generated from a pair of carbon electrodes. The mechanical and electrical stimulations could function independently to each other. The bioreactor was successfully constructed and passed the functional test and ready for actual application for tissue engineering. © 2021 Author(s). |
|
|
American Institute of Physics Inc. |
0094243X |
9780735440869 |
|
Conference Paper |
- |
177 |
20880 |
|
|
|
518 |
Apriadi W., Gani H.S., Prayitno P., Ibrahim N., Wijaya S.K. |
57205292872;57202775842;57222538092;56609777400;6506884322; |
Development of multithread acquisition system for high quality EEG signal measurement |
2021 |
Journal of Physics: Conference Series |
1816 |
1 |
012072 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103129496&doi=10.1088%2f1742-6596%2f1816%2f1%2f012072&partnerID=40&md5=8df825ddfea9b100797241af3b95358e |
Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Department of Physiology, Medical Faculty, Universitas Indonesia, Jakarta, 10430, Indonesia |
Apriadi, W., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Gani, H.S., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Prayitno, P., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia; Ibrahim, N., Department of Physiology, Medical Faculty, Universitas Indonesia, Jakarta, 10430, Indonesia; Wijaya, S.K., Department of Physics, FMIPA Universitas Indonesia, Depok, 16424, Indonesia |
This work was concerned on development of the EEG acquisition and EEG signal processing by adding active electrodes and implementing multithread techniques. By using active electrodes, mounting them on the scalp surface would be easier to capture low signals of less than 1µV. The active electrodes were used to reduce noise when transfer signals from the electrode to the acquisition systems which equipped 20 gain. The verification was performed by comparing the active and passive electrodes using NETECH MiniSIM EEG Simulator 330. The advantage of this research was to reduce time delay for EEG signal computation on 32 channels. The acquisition system was based on Raspberry Pi and ADS1299 with multithread signal treatment. Signal filtering was performed into different threads and put all the EEG features into the database. A PC was used to process signal calculation such as processing FFT, signal feature extractions, and signal analysis. These calculations were divided into several functionally independent computations. The signals of each channel were calculated into different threads. The results of this work showed the effectiveness of the multithreaded method for processing large amounts of data (32 channels of 24 bits EEG signal) with low noise levels on the active electrodes. © Published under licence by IOP Publishing Ltd. |
|
Electrodes; Acquisition systems; Active electrodes; Eeg acquisitions; EEG signal processing; Large amounts of data; Multithread techniques; Signal treatments; Transfer signals; Biomedical signal processing |
IOP Publishing Ltd |
17426588 |
|
|
Conference Paper |
Q4 |
210 |
18731 |
|
|
|
527 |
Supali T., Djuardi Y., Christian M., Iskandar E., Alfian R., Maylasari R., Destani Y., Lomiga A., Minggu D., Lew D., Bogus J., Weil G.J., Fischer P.U. |
6602742029;6507800820;57209806543;57202299885;57222748640;57222744651;57222743128;57205724071;57202307524;57196371851;57170558700;7007028568;23567680200; |
An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. Diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia |
2021 |
PLoS Neglected Tropical Diseases |
15 |
3 |
e0009294 |
|
|
|
2 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103946402&doi=10.1371%2fjournal.pntd.0009294&partnerID=40&md5=bf67e831adfbad446acbda06b08e12de |
Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Universitas Nusa Cendana, Kupang, Lasiana, Kelapa lima, Kota Kupang, Indonesia; Nusa Tenggara Timur Provincial Health Office, Oebobo, Kota Kupang, Nusa Tenggara Timur, Indonesia; Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States |
Supali, T., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Djuardi, Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Christian, M., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Iskandar, E., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Alfian, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Maylasari, R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Destani, Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Lomiga, A., Universitas Nusa Cendana, Kupang, Lasiana, Kelapa lima, Kota Kupang, Indonesia; Minggu, D., Nusa Tenggara Timur Provincial Health Office, Oebobo, Kota Kupang, Nusa Tenggara Timur, Indonesia; Lew, D., Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, United States; Bogus, J., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Weil, G.J., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Fischer, P.U., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States |
Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethyl-carbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite Wuchereria ban-crofti from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with Brugia timori infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with B. timori Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 sub-jects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant’s home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25/28, 89% vs. 8/27, 30%, P < 0.001). By 12 months after treatment, only one of 27 IDA recipients had Mf in their blood (4%) vs. 10 of 25 (40%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing B. timori Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis. © 2021 Supali et al. |
|
albendazole; antifilarial agent; diethylcarbamazine; immunoglobulin G4; ivermectin; albendazole; antifilarial agent; diethylcarbamazine; ivermectin; protozoon antibody; abdominal pain; adult; antibody titer; arthralgia; Article; body mass; Brugia; Brugian filariasis; Burkholderia pseudomallei; combination drug therapy; controlled study; coughing; daily life activity; double blind procedure; dried blood spot testing; drowsiness; drug efficacy; drug safety; drug tolerability; female; fever; filariasis; follow up; gametocyte; headache; helminthiasis; human; Indonesia; leprosy; low back pain; lymphatic filariasis; major clinical study; male; mass drug administration; microfilariasis; myalgia; pharmacokinetics; Plasmodium falciparum; prevalence; questionnaire; randomized controlled trial; Schis |
Public Library of Science |
19352727 |
|
33780481 |
Article |
Q1 |
1990 |
1322 |
|
|
|
531 |
Lazarus G., Tjoa K., Iskandar A.W.B., Louisa M., Sagwa E.L., Padayatchi N., Soetikno V. |
57214599425;57222366705;57217632802;41461551400;53464303100;6603387290;36769252100; |
The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis |
2021 |
PLoS ONE |
16 |
3 March |
e0248017 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102483457&doi=10.1371%2fjournal.pone.0248017&partnerID=40&md5=e604a5ae346e4c3a4b38a5f906459a26 |
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Windhoek, Namibia; Nairobi, Kenya; CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa |
Lazarus, G., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Tjoa, K., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Iskandar, A.W.B., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Louisa, M., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sagwa, E.L., Windhoek, Namibia, Nairobi, Kenya; Padayatchi, N., CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa; Soetikno, V., Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background Adverse events (AEs) during drug-resistant tuberculosis (DR-TB) treatment, especially with human immunodeficiency virus (HIV) co-infection, remains a major threat to poor DR-TB treatment adherence and outcomes. This meta-analysis aims to investigate the effect of HIV infection on the development of AEs during DR-TB treatment. Methods Eligible studies evaluating the association between HIV seropositivity and risks of AE occurrence in DR-TB patients were included in this systematic review. Interventional and observational studies were assessed for risk of bias using the Risk of Bias in Nonrandomized Studies of Intervention and Newcastle-Ottawa Scale tool, respectively. Random-effects meta-analysis was performed to estimate the pooled risk ratio (RR) along with their 95% confidence intervals (CIs). Results A total of 37 studies involving 8657 patients were included in this systematic review. We discovered that HIV infection independently increased the risk of developing AEs in DR-TB patients by 12% (RR 1.12 [95% CI: 1.02-1.22]; I2 = 0%, p = 0.75). In particular, the risks were more accentuated in the development of hearing loss (RR 1.44 [95% CI: 1.18-1.75]; I2 = 60%), nephrotoxicity (RR 2.45 [95% CI: 1.20-4.98], I2 = 0%), and depression (RR 3.53 [95% CI: 1.38-9.03]; I2 = 0%). Although our findings indicated that the augmented risk was primarily driven by antiretroviral drug usage rather than HIV-related immunosuppression, further studies investigating their independent effects are required to confirm our findings. Conclusion HIV co-infection independently increased the risk of developing AEs during DR-TB treatment. Increased pharmacovigilance through routine assessments of audiological, renal, and mental functions are strongly encouraged to enable prompt diagnosis and treatment in patients experiencing AEs during concomitant DR-TB and HIV treatment. Copyright: © 2021 Lazarus et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
|
antiretrovirus agent; efavirenz; ethionamide; kanamycin; lamivudine; pyrazinamide; tenofovir; tuberculostatic agent; tuberculostatic agent; adverse event; antiretroviral therapy; coinfection; confidence interval; data analysis; data extraction; data quality assessment; depression; drug resistant tuberculosis; hearing impairment; human; Human immunodeficiency virus infection; immune deficiency; meta analysis; nephrotoxicity; Newcastle-Ottawa scale; Review; statistical analysis; systematic review; adverse drug reaction; complication; depression; hearing impairment; Human immunodeficiency virus infection; kidney failure; multidrug resistant tuberculosis; Antitubercular Agents; Depression; Drug-Related Side Effects and Adverse Reactions; Hearing Loss; HIV Infections; Humans; Renal Insufficienc |
Public Library of Science |
19326203 |
|
33662024 |
Review |
Q1 |
990 |
4434 |
|
|
|
534 |
Lamontagne F., Agoritsas T., Siemieniuk R., Rochwerg B., Bartoszko J., Askie L., MacDonald H., Amin W., Bausch F.J., Burhan E., Cecconi M., Chanda D., Dat V.Q., Du B., Geduld H., Gee P., Nerina H., Hashimi M., Hunt B.J., Kabra S., Kanda S., Kawano-Dourado L., Kim Y.-J., Kissoon N., Kwizera A., Leo Y.-S., Mahaka I., Manai H., Mino G., Nsutebu E., Pshenichnaya N., Qadir N., Ranganathan S.S., Sabzwari S., Sarin R., Sharland M., Shen Y., Souza J.P., Stegemann M., Ugarte S., Venkatapuram S., Vuyiseka D., Preller J., Brignardello-Petersen R., Kum E., Qasim A., Zeraatkar D., Owen A., Guyatt G., Lytvyn L., Diaz J., Vandvik P.O., Jacobs M. |
15829826700;9734624300;23981410900;24345132600;56940778900;6603045596;57223601603;57221910483;57192706123;36058554600;16505953800;26029327700;56046962100;36131305900;36544760800;57204935223;57222260351;57222257762;55246203600;36488033400;57218352115;45561384900;7410198066;57221100878;35208486000;7004240142;56957092900;57211044922;57222258682;6603293930;6504380233;55622346400;6506124670;35240808700;23006204200;57203106412;16744841200;13205307600;23480876400;25654264800;25937500100;57079260800;55318241800;45161122100;57221470276;57206787520;57190033017;7202052634;8841196600;56600867200;13404130400;6602321455;36848322200; |
A living WHO guideline on drugs to prevent covid-19 |
2021 |
The BMJ |
372 |
|
n526 |
|
|
|
29 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102047389&doi=10.1136%2fbmj.n526&partnerID=40&md5=4b6b72a2cd8535abedd1f2abe649c5ac |
Université de Sherbrooke, Centre de Recherche Due Chu de Sherbrooke, Sherbrooke, QC, Canada; Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Magic Evidence Ecosystem Foundation, Oslo, Norway; Department of Medicine, McMaster University, Hamilton, ON, Canada; World Health Organization, Geneva, Switzerland; The Bmj, London, United Kingdom; Ministry of Health and Population, Cairo, Egypt; Geneva University Hospital, Switzerland; Infection Division, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia; Department of Anesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy; Adult Infectious Disease Centre, University Teaching Hospital, Lusaka, Zambia; Department of Infectious Diseases, Hanoi Medical University, Hanoi, Viet Nam; Peking Union Medical College Hospital, Beijing, China; Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; United States; Royal Melbourne Hospital, Melbourne, Australia; Ziauddin University, Karachi, Pakistan; Guy's and St Thomas' Nhs Foundation Trust, London, United Kingdom; All India Institute of Medical Sciences, New Delhi, India; McMaster University (Alumnus), Canada; Pulmonary Division, Heart Institute (InCor)- Hcfmusp, Medical School, University of Sao Paulo, São Paulo, Brazil; Sungkyunkwan University, School of Medicine, Samsung Medical Center, Seoul, South Korea; Department of Paediatrics and Emergency Medicine, University of British Columbia, Vancouver, Canada; Department of Anaesthesia and Critical Care, College of Health Sciences, Makerere University, Kampala, Uganda; National Center for Infectious Diseases, Singapore, Singapore; Pangaea Harare, Zimbabwe; Emergency Medical Services, Faculty of Medicine, Tunis, Tunisia; Alcivar Hospital, Guayaquil, Ecuador; Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates; Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States; University of Colombo, Colombo, Sri Lanka; Aga Khan University, Karachi, Pakistan; National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India; St. George's University Hospital, London, United Kingdom; Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; University of Sao Paulo, Sao Paulo, Brazil; Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany; Faculty of Medicine, Andres Bello University, Indisa Clinic, Santiago, Chile; King's College, London, United Kingdom; University of Stellenbosch, South Africa; University of Liverpool, Liverpool, United Kingdom; Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo, Norway; Royal Free London Nhs Foundation Trust, London, United Kingdom; Research Institute, Hospital Do Coração (HCor), São Paulo, Brazil |
Lamontagne, F., Université de Sherbrooke, Centre de Recherche Due Chu de Sherbrooke, Sherbrooke, QC, Canada; Agoritsas, T., Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Magic Evidence Ecosystem Foundation, Oslo, Norway; Siemieniuk, R., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada; Rochwerg, B., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada; Bartoszko, J., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Askie, L., World Health Organization, Geneva, Switzerland; MacDonald, H., The Bmj, London, United Kingdom; Amin, W., Ministry of Health and Population, Cairo, Egypt; Bausch, F.J., Geneva University Hospital, Switzerland; Burhan, E., Infection Division, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Indonesia; Cecconi, M., Department of Anesthesia and Intensive Care Medicine, Humanitas Clinical and Research Center-IRCCS, Rozzano, Italy; Chanda, D., Adult Infectious Disease Centre, University Teaching Hospital, Lusaka, Zambia; Dat, V.Q., Department of Infectious Diseases, Hanoi Medical University, Hanoi, Viet Nam; Du, B., Peking Union Medical College Hospital, Beijing, China; Geduld, H., Division of Emergency Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Gee, P., United States; Nerina, H., Royal Melbourne Hospital, Melbourne, Australia; Hashimi, M., Ziauddin University, Karachi, Pakistan; Hunt, B.J., Guy's and St Thomas' Nhs Foundation Trust, London, United Kingdom; Kabra, S., All India Institute of Medical Sciences, New Delhi, India; Kanda, S., McMaster University (Alumnus), Canada; Kawano-Dourado, L., Pulmonary Division, Heart Institute (InCor)- Hcfmusp, Medical School, University of Sao Paulo, São Paulo, Brazil, Research Institute, Hospital Do Coração (HCor), São Paulo, Brazil; Kim, Y.-J., Sungkyunkwan University, School of Medicine, Samsung Medical Center, Seoul, South Korea; Kissoon, N., Department of Paediatrics and Emergency Medicine, University of British Columbia, Vancouver, Canada; Kwizera, A., Department of Anaesthesia and Critical Care, College of Health Sciences, Makerere University, Kampala, Uganda; Leo, Y.-S., National Center for Infectious Diseases, Singapore, Singapore; Mahaka, I., Pangaea Harare, Zimbabwe; Manai, H., Emergency Medical Services, Faculty of Medicine, Tunis, Tunisia; Mino, G., Alcivar Hospital, Guayaquil, Ecuador; Nsutebu, E., Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates; Pshenichnaya, N., Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation; Qadir, N., Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States; Ranganathan, S.S., University of Colombo, Colombo, Sri Lanka; Sabzwari, S., Aga Khan University, Karachi, Pakistan; Sarin, R., National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India; Sharland, M., St. George's University Hospital, London, United Kingdom; Shen, Y., Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; Souza, J.P., University of Sao Paulo, Sao Paulo, Brazil; Stegemann, M., Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Infectious Diseases and Respiratory Medicine, Berlin, Germany; Ugarte, S., Faculty of Medicine, Andres Bello University, Indisa Clinic, Santiago, Chile; Venkatapuram, S., King's College, London, United Kingdom; Vuyiseka, D., University of Stellenbosch, South Africa; Preller, J., World Health Organization, Geneva, Switzerland; Brignardello-Petersen, R., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Kum, E., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Qasim, A., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Zeraatkar, D., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Owen, A., University of Liverpool, Liverpool, United Kingdom; Guyatt, G., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Department of Medicine, McMaster University, Hamilton, ON, Canada; Lytvyn, L., Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; Diaz, J., World Health Organization, Geneva, Switzerland; Vandvik, P.O., Magic Evidence Ecosystem Foundation, Oslo, Norway, Department of Health Economics and Health Management, Institute for Health and Society, University of Oslo, Oslo, Norway; Jacobs, M., Royal Free London Nhs Foundation Trust, London, United Kingdom |
Clinical question What is the role of drugs in preventing covid-19? Why does this matter? There is widespread interest in whether drug interventions can be used for the prevention of covid-19, but there is uncertainty about which drugs, if any, are effective. The first version of this living guideline focuses on the evidence for hydroxychloroquine. Subsequent updates will cover other drugs being investigated for their role in the prevention of covid-19. Recommendation The guideline development panel made a strong recommendation against the use of hydroxychloroquine for individuals who do not have covid-19 (high certainty). How this guideline was created This living guideline is from the World Health Organization (WHO) and provides up to date covid-19 guidance to inform policy and practice worldwide. Magic Evidence Ecosystem Foundation (MAGIC) provided methodological support. A living systematic review with network analysis informed the recommendations. An international guideline development panel of content experts, clinicians, patients, an ethicist and methodologists produced recommendations following standards for trustworthy guideline development using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Understanding the new recommendation The linked systematic review and network meta-analysis (6 trials and 6059 participants) found that hydroxychloroquine had a small or no effect on mortality and admission to hospital (high certainty evidence). There was a small or no effect on laboratory confirmed SARS-CoV-2 infection (moderate certainty evidence) but probably increased adverse events leading to discontinuation (moderate certainty evidence). The panel judged that almost all people would not consider this drug worthwhile. In addition, the panel decided that contextual factors such as resources, feasibility, acceptability, and equity for countries and healthcare systems were unlikely to alter the recommendation. The panel considers that this drug is no longer a research priority and that resources should rather be oriented to evaluate other more promising drugs to prevent covid-19. Updates This is a living guideline. New recommendations will be published in this article and signposted by update notices to this guideline. Readers note This is the first version of the living guideline for drugs to prevent covid-19. It complements the WHO living guideline on drugs to treat covid-19. When citing this article, please consider adding the update number and date of access for clarity. © Published by the BMJ Publishing Group Limited. |
|
hydroxychloroquine; hydroxychloroquine; immunologic factor; coronavirus disease 2019; drug use; health care policy; high risk patient; human; immune response; infection prevention; nonhuman; practice guideline; Review; Severe acute respiratory syndrome coronavirus 2; World Health Organization; chemoprophylaxis; clinical decision making; drug effect; epidemiology; practice guideline; prevention and control; procedures; risk assessment; uncertainty; Chemoprevention; Clinical Decision-Making; COVID-19; Humans; Hydroxychloroquine; Immunologic Factors; Risk Assessment; SARS-CoV-2; Uncertainty; World Health Organization |
BMJ Publishing Group |
09598146 |
|
33649077 |
Review |
Q1 |
1831 |
1579 |
|
|
|
546 |
Siste K., Sen L.T. |
55644113100;57219034101; |
Ascending Pattern of Alcohol Use and Underage Drinking in Asia: A Commentary on the Article by Assanangkornchai and Vichitkunakorn (2020) |
2021 |
Alcoholism: Clinical and Experimental Research |
45 |
3 |
|
496 |
499 |
|
1 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100845814&doi=10.1111%2facer.14556&partnerID=40&md5=c99d4fa613d254d149143468117898a3 |
Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo General Hospital, Jakarta, Indonesia |
Siste, K., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Sen, L.T., Department of Psychiatry, Faculty of Medicine, Universitas Indonesia – Cipto Mangunkusumo General Hospital, Jakarta, Indonesia |
[No abstract available] |
|
alcohol; adolescent; adulthood; advertising; alcohol consumption; alcohol intoxication; alcohol withdrawal syndrome; alcoholic beverage; alcoholism; brain cortex; brain stem; corpus callosum; cultural factor; depression; drinking behavior; environmental factor; female; gray matter volume; groups by age; hippocampus; human; India; Indonesia; limbic cortex; male; mortality; Note; peer pressure; prefrontal cortex; prevalence; priority journal; psychological resilience; sex difference; social psychology; Southeast Asia; suicide attempt; Thailand; trend study; underage drinking; white matter; World Health Organization |
Blackwell Publishing Ltd |
01456008 |
|
33486766 |
Note |
Q1 |
1267 |
3019 |
|
|
|
547 |
Tsoi K., Yiu K., Lee H., Cheng H.-M., Wang T.-D., Tay J.-C., Teo B.W., Turana Y., Soenarta A.A., Sogunuru G.P., Siddique S., Chia Y.-C., Shin J., Chen C.-H., Wang J.-G., Kario K., the HOPE Asia Network |
16065259000;24167446900;57271749300;57026688600;7405566618;24330212600;23570166200;56083326000;6507634613;26428524900;57210091066;57204080905;54791393300;7501963868;57211730247;7102633390; |
Applications of artificial intelligence for hypertension management |
2021 |
Journal of Clinical Hypertension |
23 |
3 |
|
568 |
574 |
|
4 |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100377966&doi=10.1111%2fjch.14180&partnerID=40&md5=cdd3526a471a2db59f4ca490ffd9d59b |
SH Big Data Decision and Analytics Research Centre, Shatin, Hong Kong; JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Department of Neurology, School of Medicine and health Sciences, Atma Jaya Catholic University of Indonesia, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Department of Cardiology, MIOT international hospital, Chennai, India; Punjab Medical Center, Lahore, Pakistan; Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia; Faculty of Medicine, Department of Primary Care Medicine, University of Malaya, Kuala Lumpur, Malaysia; Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan |
Tsoi, K., SH Big Data Decision and Analytics Research Centre, Shatin, Hong Kong, JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Yiu, K., SH Big Data Decision and Analytics Research Centre, Shatin, Hong Kong; Lee, H., JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong; Cheng, H.-M., Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan, Center for Evidence-based Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Wang, T.-D., Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan, Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; Tay, J.-C., Department of General Medicine, Tan Tock Seng Hospital, Singapore, Singapore; Teo, B.W., Division of Nephrology Department of Medicine, Yong Loo Lin School of Medicine, Singapore, Singapore; Turana, Y., Department of Neurology, School of Medicine and health Sciences, Atma Jaya Catholic University of Indonesia, Indonesia; Soenarta, A.A., Department of Cardiology and Vascular Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia; Sogunuru, G.P., Department of Cardiology, MIOT international hospital, Chennai, India; Siddique, S., Punjab Medical Center, Lahore, Pakistan; Chia, Y.-C., Department of Medical Sciences, School of Healthcare and Medical Sciences, Sunway University, Bandar Sunway, Malaysia, Faculty of Medicine, Department of Primary Care Medicine, University of Malaya, Kuala Lumpur, Malaysia; Shin, J., Faculty of Cardiology Service, Hanyang University Medical Center, Seoul, South Korea; Chen, C.-H., Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Wang, J.-G., Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Kario, K., Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; the HOPE Asia Network |
The prevalence of hypertension is increasing along with an aging population, causing millions of premature deaths annually worldwide. Low awareness of blood pressure (BP) elevation and suboptimal hypertension diagnosis serve as the major hurdles in effective hypertension management. The advent of artificial intelligence (AI), however, sheds the light of new strategies for hypertension management, such as remote supports from telemedicine and big data-derived prediction. There is considerable evidence demonstrating the feasibility of AI applications in hypertension management. A foreseeable trend was observed in integrating BP measurements with various wearable sensors and smartphones, so as to permit continuous and convenient monitoring. In the meantime, further investigations are advised to validate the novel prediction and prognostic tools. These revolutionary developments have made a stride toward the future model for digital management of chronic diseases. © 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. |
|
antihypertensive agent; antihypertensive therapy; artificial intelligence; blood pressure monitoring; blood pressure regulation; disease burden; feasibility study; health care cost; human; hypertension; incidence; lifestyle modification; mobile application; outcome assessment; prediction; prognosis; Review; telemedicine; trend study; validation process; aged; artificial intelligence; hypertension; telemedicine; Aged; Artificial Intelligence; Humans; Hypertension; Telemedicine |
John Wiley and Sons Inc |
15246175 |
|
33533536 |
Review |
Q2 |
909 |
5078 |
|
|
|
556 |
Ariestine D.A., Sari N.K., Rinaldi I., Abdullah M. |
57219412521;57209884078;23475122400;7103393434; |
Quality of life in older survivors of non-Hodgkin's lymphoma who received chemotherapy and related factors |
2021 |
Journal of Geriatric Oncology |
12 |
2 |
|
326 |
331 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092628404&doi=10.1016%2fj.jgo.2020.09.002&partnerID=40&md5=92d66bbff89e86b5c41bc8d40476f78e |
Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia; Division of Geriatric Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; National Cancer Center-Dharmais Cancer Hospital, Jakarta, Indonesia; Division of Hemato-oncolocy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia; Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia |
Ariestine, D.A., Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia, Division of Geriatric Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia; Sari, N.K., Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia, National Cancer Center-Dharmais Cancer Hospital, Jakarta, Indonesia; Rinaldi, I., Division of Hemato-oncolocy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia; Abdullah, M., Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Indonesia |
Introduction: Cancer and its treatment have a broad impact on patients' Quality of Life (QoL). Previous researches showed that many factors in Comprehensive Geriatric Assessment (CGA) affect QoL. CGA could predict toxicity, overall survival rate and can help adjust the choice and intensity of treatment in each patient. However, there has been no research explicitly exploring factors related to the QoL in older patients with Non-Hodgkin's Lymphoma (NHL). This research aims to explore the how factors in CGA relate to the QoL in older patients with NHL. Materials and Method: The study design was cross-sectional in NHL patients aged ≥ 60 years, research was conducted in Integrated Geriatric Polyclinic and Hemato-Oncology Polyclinic of three public hospitals in Jakarta, during March–August 2019. Results: There were 62 subjects, with a median age of 66 years, 56.5% male. The result showed that most of the patients have a good QoL, based on each domain of SF-36 and EORTC QLQ-C30. In multivariate analysis, it was found that depression and frailty status were related to PCS SF-36 domain with PR 12.086 (95% CI 1.596–92.124) and PR 5.622 (95% CI 1.060–29.807), respectively. Multivariate analysis with SF-36's Mental Component Summary (MCS) showed a significant relationship with depression status with PR 24.400 (95% CI 2.961–140.539). While the results of multivariate analysis with the EORTC QLQ-C30 functional scale showed a significant relationship with the ECOG performance score with PR 171 (95% CI 8.470–3452.28). Discussions: After multivariate analysis, only frailty status, depression status and ECOG performance score have a statistically significant relationship. © 2020 Elsevier Ltd |
|
antineoplastic agent; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; Abbreviated Mental Test; adult; aged; Barthel index; Barthel Index Activities of Daily Living; body mass; cancer chemotherapy; cancer survivor; clinical evaluation; comorbidity; controlled study; cross-sectional study; Cumulative Illness Rating for Geriatrics; Cumulative Illness Rating Scale; demography; diffuse large B cell lymphoma; ECOG Performance Status; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; female; geriatric assessment; Geriatric Depression Scale; human; Indonesia; Karnofsky Performance Status; Lawton instrumental activities of daily living scale; Letter; major clinical study; male; mental test; middle aged; Mini Nutrit |
Elsevier Ltd |
18794068 |
|
33008767 |
Letter |
Q2 |
1032 |
4192 |
|
|
